ATRA Atara Biotherapeutics Inc
3,131
$0.698
$0.0047
(0.68%)
| Watchers | 3,131 |
| 52-Wk Low | $0.1986 |
| 52-Wk High | $2.54 |
| Market Cap | $83.48M |
| Volume | 470,887.00 |
| 52-Wk High | $2.54 |
| 52-Wk Low | $0.1986 |
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDABusiness Wire • 2 days ago
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...
Share to Feed
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...
Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Atara Biotherapeutics (ATRA Research Report) and Embecta Corporation...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
StockNews.com cut shares of Atara Biotherapeutics (NASDAQ:ATRA - Free Report) from a hold rating to a sell rating in a report released on Thursday morning. Atara Biotherapeutics Stock Down 0.9...
Analysts fell to the sidelines weighing in on Affimed (AFMD Research Report) and Atara Biotherapeutics (ATRA Research Report) with neutral rati...
Atara Biotherapeutics ( NASDAQ:ATRA ) Full Year 2023 Results Key Financial Results Net loss: US$276.1m (loss widened by...